BACKGROUND AND PURPOSE: We have previously shown that lipid mediators, produced by phospholipase D and C, are generated in OX(1) orexin receptor signalling with high potency, and presumably mediate some of the physiological responses to orexin. In this study, we investigated whether the ubiquitous phospholipase A(2) (PLA(2)) signalling system is also involved in orexin receptor signalling. EXPERIMENTAL APPROACH: Recombinant Chinese hamster ovary-K1 cells, expressing human OX(1) receptors, were used as a model system. Arachidonic acid (AA) release was measured from (3)H-AA-labelled cells. Ca(2+) signalling was assessed using single-cell imaging. KEY RESULTS: Orexins strongly stimulated [(3)H]-AA release (maximally 4.4-fold). Orexin-A was somewhat more potent than orexin-B (pEC(50) = 8.90 and 8.38 respectively). The concentration-response curves appeared biphasic. The release was fully inhibited by the potent cPLA(2) and iPLA(2) inhibitor, methyl arachidonyl fluorophosphonate, whereas the iPLA(2) inhibitors, R- and S-bromoenol lactone, caused only a partial inhibition. The response was also fully dependent on Ca(2+) influx, and the inhibitor studies suggested involvement of the receptor-operated influx pathway. The receptor-operated pathway, on the other hand, was partially dependent on PLA(2) activity. The extracellular signal-regulated kinase, but not protein kinase C, were involved in the PLA(2) activation at low orexin concentrations. CONCLUSIONS AND IMPLICATIONS: Activation of OX(1) orexin receptors induced a strong, high-potency AA release, possibly via multiple PLA(2) species, and this response may be important for the receptor-operated Ca(2+) influx. The response coincided with other high-potency lipid messenger responses, and may interact with these signals.
BACKGROUND AND PURPOSE: We have previously shown that lipid mediators, produced by phospholipase D and C, are generated in OX(1) orexin receptor signalling with high potency, and presumably mediate some of the physiological responses to orexin. In this study, we investigated whether the ubiquitous phospholipase A(2) (PLA(2)) signalling system is also involved in orexin receptor signalling. EXPERIMENTAL APPROACH: Recombinant Chinese hamster ovary-K1 cells, expressing human OX(1) receptors, were used as a model system. Arachidonic acid (AA) release was measured from (3)H-AA-labelled cells. Ca(2+) signalling was assessed using single-cell imaging. KEY RESULTS: Orexins strongly stimulated [(3)H]-AA release (maximally 4.4-fold). Orexin-A was somewhat more potent than orexin-B (pEC(50) = 8.90 and 8.38 respectively). The concentration-response curves appeared biphasic. The release was fully inhibited by the potent cPLA(2) and iPLA(2) inhibitor, methyl arachidonyl fluorophosphonate, whereas the iPLA(2) inhibitors, R- and S-bromoenol lactone, caused only a partial inhibition. The response was also fully dependent on Ca(2+) influx, and the inhibitor studies suggested involvement of the receptor-operated influx pathway. The receptor-operated pathway, on the other hand, was partially dependent on PLA(2) activity. The extracellular signal-regulated kinase, but not protein kinase C, were involved in the PLA(2) activation at low orexin concentrations. CONCLUSIONS AND IMPLICATIONS: Activation of OX(1) orexin receptors induced a strong, high-potency AA release, possibly via multiple PLA(2) species, and this response may be important for the receptor-operated Ca(2+) influx. The response coincided with other high-potency lipid messenger responses, and may interact with these signals.
Authors: Tomas Holmqvist; Lisa Johansson; Marie Ostman; Sylwia Ammoun; Karl E O Akerman; Jyrki P Kukkonen Journal: J Biol Chem Date: 2004-12-16 Impact factor: 5.157
Authors: T Sakurai; A Amemiya; M Ishii; I Matsuzaki; R M Chemelli; H Tanaka; S C Williams; J A Richardson; G P Kozlowski; S Wilson; J R Arch; R E Buckingham; A C Haynes; S A Carr; R S Annan; D E McNulty; W S Liu; J A Terrett; N A Elshourbagy; D J Bergsma; M Yanagisawa Journal: Cell Date: 1998-02-20 Impact factor: 41.582
Authors: Kim P Larsson; Hanna M Peltonen; Genevieve Bart; Lauri M Louhivuori; Annika Penttonen; Miia Antikainen; Jyrki P Kukkonen; Karl E O Akerman Journal: J Biol Chem Date: 2004-11-10 Impact factor: 5.157
Authors: Carine M Mounier; Farideh Ghomashchi; Margaret R Lindsay; Scott James; Alan G Singer; Robert G Parton; Michael H Gelb Journal: J Biol Chem Date: 2004-03-08 Impact factor: 5.157
Authors: Christopher M Jenkins; David J Mancuso; Wei Yan; Harold F Sims; Beverly Gibson; Richard W Gross Journal: J Biol Chem Date: 2004-09-10 Impact factor: 5.157
Authors: M Skrzypski; T T Le; P Kaczmarek; E Pruszynska-Oszmalek; P Pietrzak; D Szczepankiewicz; P A Kolodziejski; M Sassek; A Arafat; B Wiedenmann; K W Nowak; M Z Strowski Journal: Diabetologia Date: 2011-04-21 Impact factor: 10.122
Authors: Paul Coleman; Luis de Lecea; Anthony Gotter; Jim Hagan; Daniel Hoyer; Thomas Kilduff; Jyrki P Kukkonen; Rod Porter; John Renger; Jerome M Siegel; Gregor Sutcliffe; Neil Upton; Christopher J Winrow Journal: IUPHAR BPS Guide Pharm CITE Date: 2021-09-02